(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.61%) $83.34
(-1.16%) $1.619
(0.02%) $2 347.70
(0.93%) $27.51
(0.17%) $923.70
(-0.07%) $0.934
(-0.03%) $11.02
(-0.11%) $0.800
(0.00%) $92.17
1.06% € 100.52
Live Chart Being Loaded With Signals
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices...
Stats | |
---|---|
Volumen de hoy | 823.00 |
Volumen promedio | 592.00 |
Capitalización de mercado | 174.42B |
EPS | €0 ( 2024-04-17 ) |
Próxima fecha de ganancias | ( €0 ) 2024-07-17 |
Last Dividend | €0.510 ( 2023-07-13 ) |
Next Dividend | €0 ( N/A ) |
P/E | 33.51 |
ATR14 | €0 (0.00%) |
Abbott Laboratories Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Abbott Laboratories Finanzas
Annual | 2023 |
Ingresos: | €40.11B |
Beneficio Bruto: | €22.13B (55.18 %) |
EPS: | €3.28 |
FY | 2023 |
Ingresos: | €40.11B |
Beneficio Bruto: | €22.13B (55.18 %) |
EPS: | €3.28 |
FY | 2022 |
Ingresos: | €43.65B |
Beneficio Bruto: | €24.51B (56.15 %) |
EPS: | €3.99 |
FY | 2021 |
Ingresos: | €43.08B |
Beneficio Bruto: | €24.54B (56.97 %) |
EPS: | €4.00 |
Financial Reports:
No articles found.
Abbott Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.470 (N/A) |
€0.470 (N/A) |
€0.510 (N/A) |
€0.510 (N/A) |
€0.510 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.325 | 2008-01-11 |
Last Dividend | €0.510 | 2023-07-13 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 64 | -- |
Total Paid Out | €22.13 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.9 | -- |
Div. Sustainability Score | 4.40 | |
Div.Growth Potential Score | 7.33 | |
Div. Directional Score | 5.87 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
MTE.DE | Ex Dividend Junior | 2023-07-07 | Quarterly | 0 | 0.00% | |
68V.DE | Ex Dividend Knight | 2023-08-07 | Quarterly | 0 | 0.00% | |
WAF.DE | Ex Dividend Junior | 2023-05-08 | Annually | 0 | 0.00% | |
FIE.DE | Ex Dividend Junior | 2023-07-14 | Annually | 0 | 0.00% | |
PAH3.DE | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
AP2.DE | Ex Dividend Knight | 2023-11-22 | Quarterly | 0 | 0.00% | |
HDI.DE | Ex Dividend Knight | 2023-08-30 | Quarterly | 0 | 0.00% | |
RWE.DE | Ex Dividend Junior | 2023-05-05 | Annually | 0 | 0.00% | |
CAR.DE | Ex Dividend Knight | 2023-06-06 | Annually | 0 | 0.00% | |
KEL.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.140 | 1.500 | 7.21 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.148 | 1.500 | 9.47 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.474 | -1.000 | 5.26 | -5.26 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 22.04 | 1.000 | 2.95 | 2.95 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.50 | 2.00 | 8.83 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.45 | 2.00 | 8.77 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.552 | 1.000 | 4.13 | 4.13 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.158 | 1.000 | 8.84 | 8.84 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.40 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 33.43 | 1.000 | 6.72 | 0 | [1 - 100] |
returnOnEquityTTM | 0.148 | 2.50 | 9.66 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.45 | 2.00 | 9.18 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.971 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.50 | 2.00 | 8.83 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.474 | 1.500 | 5.26 | -5.26 | [0 - 1] |
pegRatioTTM | 6.47 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.152 | 1.000 | 8.71 | 0 | [0.1 - 0.5] |
Total Score | 7.33 |
Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico